Compare BAFN & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAFN | BCTX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 28.8M |
| IPO Year | 2021 | 2025 |
| Metric | BAFN | BCTX |
|---|---|---|
| Price | $6.53 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 13.7K | ★ 179.7K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 133.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.72 | $0.61 |
| 52 Week High | $19.15 | $14.68 |
| Indicator | BAFN | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 38.08 |
| Support Level | $6.31 | $0.68 |
| Resistance Level | $8.26 | $4.42 |
| Average True Range (ATR) | 0.45 | 0.25 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 0.53 | 24.39 |
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.